Clinical Implications of MajesTEC-1

Opinion
Video

Amrita Y. Krishnan, MD, and Binod Dhakal, MD, discuss the clinical implications of data from MajesTEC-1 and provide key takeaways on the evolving relapsed/refractory multiple myeloma treatment landscape.

Video content above is prompted by the following questions:

  • Based on the long-term efficacy and safety data presented for teclistamab in the MajesTEC-1 trial, what are your key takeaways or clinical implications for the use of this agent in patients with relapsed/refractory multiple myeloma (R/R MM)?
  • Despite the promising results with teclistamab, what potential unmet needs or areas for further research and development remain in the treatment of R/R MM?
Related Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Amrita Y. Krishnan, MD, and Binod Dhakal, MD
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
This series features 2 KOLs.
This series features 2 KOLs.
4 KOLs are featured in this program.
Related Content
Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials

Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials

Zachary M. Avigan, MD;Joshua Richter, MD
June 14th 2024
Article

The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024
Podcast

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Data from the PERSEUS trial also show that responses deepened over time in both arms among patients with transplant-eligible multiple myeloma.

Daratumumab Combo Yields MRD-Negative Status in Transplant-Eligible Myeloma

Chris Ryan
June 4th 2024
Article

Data from the PERSEUS trial also show that responses deepened over time in both arms among patients with transplant-eligible multiple myeloma.

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma

Joselle Cook, MBBS, Mayo Clinic;Matthew James Pianko, MD;Luciano Costa, MD, PhD;Timothy Schmidt, MD
August 14th 2023
Podcast

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Prolonged PFS Observed in Isatuximab Combo in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

Prolonged PFS Observed in Isatuximab Combo in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

Ryan Scott
June 4th 2024
Article

Isatuximab, bortezomib, lenalidomide, and dexamethasone prolonged PFS vs bortezomib, lenalidomide, and dexamethasone, in a subsect of patients with multiple myeloma.

MAIC Study Finds Similar Results With Linvoseltamab/Teclistamab in R/R Multiple Myeloma

MAIC Study Finds Similar Results With Linvoseltamab/Teclistamab in R/R Multiple Myeloma

Brielle Benyon
June 3rd 2024
Article

Similar outcomes were noted when linvoseltamab and teclistamab were analyzed as treatments for patients with relapsed/refractory multiple myeloma.